This resulted in effective genome editing of VEGFA within tumor cells, a reduction in VEGFA expression, suppression of lung metastasis and orthotopic OS severity, as well as a decline in angiogenesis and bone lesions, all without any noticeable toxicity. The gene discussed is VEGFA; the disease is neoplasm.